


Novartis - Focus on Europe




www.novartis.com

A therapeutic revolution for every decade



Priority for R&D

Novartis is reimagining medicine and is committed to delivering new treatments that transform patients' lives. Our approach to R&D pushes the boundaries of science to find solutions where there is unmet medical need in four main areas:



109 clinical projects incl. 41 ongoing phase III programmes




€7.8 billion R&D investments

Novartis, a committed player in...*

Ethical standards


Novartis is committed to conducting thorough due diligence processes to identify, address, evaluate and communicate the risks of involvement with adverse human rights, ethical and compliance issues.

Equal opportunities




Environment

Our ambition is to be a leader in environmental transition thanks to ambitious assembled targets for 2025 and 2030 involving our activities and those of our partners in the following areas:




*For more info, see the Novartis in Society Integrated Report 2023

Worldwide access




Novartis in Europe*



*European Union & Switzerland. **Full Time Equivalent. ***Direct, indirect and induced.

Sites in Europe

Manufacturing sites		
Large Molecules	Small Molecules	Cell & Gene
1 Schafftenau (2)	7 Puurs	5 Stein
2 Kundl	8 Târgu Mureş	
3 Huningue	4 Ljubljana	
4 Menges	4 Menges	
5 Stein	6 Schweizerhalle	
6 Basel	9 Stein	
	10 Wehr	
	10 Torre	
		RLT
		11 Ivrea
		11 Saluggia
		12 Baarle-Nassau
		13 Zaragoza




The EU in the current geopolitical context

Europe's resilience and economic security will depend on its ability to attract innovation.


We welcome the focus on security of supply and open strategic autonomy, and remain dedicated to reimagining medicines to provide patients with life-saving treatments all over the world.

Digital tools and Artificial Intelligence (AI) have become increasingly important when it comes to the development and delivery of medicines, and we are committed to be a frontrunner in this field.

We look forward to working with the new political leadership to make sure that Europe remains a leader in healthcare.



What do we need to remain competitive?



Ensuring (market) access and availability



Medicines have no value if they don't reach patients across the continent. The absorption of innovation by member states is therefore key.



Shortages are still happening and we need to tackle the root causes, together.



Attractive IP and regulatory framework



Regulatory Data Protection is a key element for investment decisions. The General Pharmaceutical Legislation should not weaken this crucial incentive.



Prospective advanced therapies will need a future-proof system, and the use of digital tools, including AI, will be key.



Level playing field on environmental legislation



We fully support the ambition of a greener Europe (and world). Europe needs to be a front-runner in environmental standards, but by upholding the industry's competitiveness.



New legislation should include adequate transition periods, and make sure that alternatives are available.



Key EU initiatives that we are following/actively engaging:

- General Pharma Legislation
- Critical Medicines Alliance
- EU List of Critical Medicines
- European Green Deal, including Urban Waste Water Treatment Directive (UWWTD) and PFAS
- Biotech and Biomanufacturing initiative

Other initiatives we are closely monitoring:

- Patent package
- AI Act
- Letta/ Draghi reports
- IPCEI "Med4Cure"
- CS3D/CSRD
- Antwerp Declaration